Kidney Cancer Journal 3
Michael B. Atkins, MD
Lombardi Comprehensive Cancer Center
Professor of Oncology and Medicine,
Georgetown University Medical Center-
Washington, DC
Arie Belldegrun, MD
David Geffen School of Medicine
at UCLA
Los Angeles, California
Steven Campbell, MD
Cleveland Clinic Foundation
Cleveland, Ohio
Toni K. Choueiri, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
Janice P. Dutcher, MD
Associate Director, Cancer Research
Foundation of New York
Chappaqua, New York
Timothy Eisen, MD
University of Cambridge
Department of Oncology,
Addenbrooke's Hospital
Cambridge, UK
Paul Elson, PhD
Cleveland Clinic Foundation
Cleveland, Ohio
Bernard Escudier, MD
Institut Gustave-Roussy
Villejuif, France
James H. Finke, PhD
Cleveland Clinic Lerner College of
Medicine of Case Western Reserve
University
Cleveland, Ohio
Keith T. Flaherty, MD
Lecturer, Department of Medicine,
Harvard Medical School
Director of Developmental
Therapeutics, Cancer Center
Massachusetts General Hospital
Boston, Massachusetts
Daniel J. George, MD
Duke Clinical Research Institute
Durham, North Carolina
Inderbir S. Gill, MD
USC Institute of Urology
University of Southern California
Los Angeles, California
Gary Hudes, MD
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Thomas Hutson, DO, PharmD
Baylor University Medical Center
Dallas, Texas
Eric Jonasch, MD
MD Anderson Cancer Center
of the University of Texas
Houston, Texas
Eugene D. Kwon, MD
Mayo Clinic
Rochester, Minnesota
Bradley C. Leibovich, MD
Mayo Clinic
Rochester, Minnesota
David Nanus, MD
New York Presbyterian Hospital-
Weill Cornell Medical Center
New York, New York
Leslie Oleksowicz, MD
College of Medicine
University of Cincinnati
Medical Center
Cincinnati, Ohio
Allan Pantuck, MD
David Geffen School of Medicine
at UCLA
Los Angeles, California
W. Kimryn Rathmell, MD, PhD
Director, Division of Hematology
Oncology
Professor, Department of Clinical
Medicine and Cancer Biology
Vanderbilt University
Nashville, Tennessee
Paul Russo, MD
Memorial Sloan-Kettering
Cancer Center
New York, New York
Ihor S. Sawczuk, MD
Hackensack University
Medical Center
Hackensack, New Jersey
Domenic A. Sica, MD
Medical College of Virginia
Richmond, Virginia
Jeffrey A. Sosman, MD
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
Nizar Tannir, MD
MD Anderson Cancer Center
Houston, Texas
Nicholas J. Vogelzang, MD
Comprehensive Cancer Centers
of Nevada
Las Vegas, Nevada
EDITORIAL ADVISORY BOARD
Kidney Cancer Journal Author Guidelines
Scope of Manuscripts
Kidney Cancer Journal considers the following types of manuscripts for publication:
• Reviews that summarize and synthesize peer-reviewed literature to date on relevant
topics in a scholarly fashion and format.
• Original contributions based on original, basic, clinical, translational, epidemiological,
or prevention studies relating to kidney cancer that are well documented, novel, and
significant.
• Letters to the Editor on timely and relevant subjects pertaining to the diagnosis and
treatment of renal cell carcinoma.
• Clinical case studies.
Manuscript Submission
Authors are required to submit their manuscripts in an electronic format, preferably by
email to the Editor-in-Chief, Robert A. Figlin, MD, at robert.figlin@cshs.org. Please provide
in a word processing program. Images should be submitted electronically as well.
All material reproduced from previously published, copyrighted material should contain
a full credit line acknowledging the original source. The author is responsible for obtaining
this permission.
Contact information
List all authors, including mailing address, titles and affiliations, phone, fax, and email.
Please note corresponding author.
Peer Review and Editing
Manuscripts will be peer reviewed. Accepted manuscripts will be edited for clarity,
spelling, punctuation, grammar, and consistency with American Medical Association
(AMA) style. Authors whose manuscripts are not initially accepted may have the opportunity
to revise the manuscript based on recommendations from peer reviewers and at the
discretion of the Editor-in-Chief.
Conflict of Interest
Kidney Cancer Journal policy requires that authors reveal to the Editor-in-Chief any relationships
that they believe could be construed as resulting in an actual, potential, or apparent
conflict of interest with regard to the manuscript submitted for review. Authors
must disclose this information in the covering letter accompanying their submission.
Manuscript Preparation
Length: Full-length manuscripts should not exceed 4000 words, including references.
Please limit the reference list to 50 citations. Manuscripts should be accompanied by figures
and/or tables. Generally 4-5 figures and 2-3 tables are preferred for each manuscript.
Please include a brief description to accompany these items, as well as a legend for all abbreviations.
Manuscripts should not contain an abstract but an introduction is recommended.
Spacing: One space after periods. Manuscripts should be double spaced.
References
All submissions should have references that are referred to in the text by superscripted
numbers and that conform to AMA style.
Example:
Lewczuk J, Piszko P, Jagas J, et al. Prognostic factors in medically treated patients with
chronic pulmonary embolism. Chest. 2001;119:818-823.
Copyright
Manuscripts and accompanying material are accepted for exclusive publication in the Kidney
Cancer Journal. None of the contents may be reproduced without permission of the
Kidney Cancer Journal.
To request permission, please contact Stu Chapman, Executive Editor, (516) 356-5006;
Publication ethics
As an official publication of the Kidney Cancer Association, Kidney Cancer Journal (KCJ)
is committed to maintaining the highest standards of publication ethics and abides by
Code of Conduct of Committee on Publication Ethics (COPE), and aims to adhere to its
Best Practice Guidelines. Please refer to COPE flowcharts for further guidance. Manuscript
authors, editors, and reviewers are expected to be aware of, and comply with, the best
practices in publication ethics. Authors are expected to have knowledge of best practice
in publication ethics in regard to, but not limited to, authorship, dual submission, plagiarism,
manipulation of data/figures, competing interests and compliance with policies on
research ethics.
Policy on use of human subjects
The clinical research studies involving the use of human subjects should inform that
study has been carried out in accordance with The Code of Ethics of the World Medical
Association (Declaration of Helsinki) for experiments involving humans. The manuscript
should be in line with the Recommendations for the Conduct, Reporting, Editing and
Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative
human populations (sex, age and ethnicity) as per those recommendations. Authors
should include a statement in the manuscript that informed consent was obtained for
experimentation with human subjects. The privacy rights of human subjects must always
be observed. Patients’ and volunteers’ names, initials, and hospital numbers should not
be used.
Policy on use of animals
Studies involving experiments with animals must state that their care was in accordance
with institution guidelines. All animal experiments should comply with the appropriate
standard guidelines/act for the care and use of Laboratory animals and the authors
should clearly indicate in the manuscript that such guidelines have been followed.
Studies involving experiments with animals must state that their care was in accordance
with institution guidelines. Authors must state in their manuscript how the identity of
the cell line was confirmed.
link